{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/","result":{"pageContext":{"chapter":{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation","depth":2,"htmlHeader":"<!-- begin field 5631257a-041a-4295-874a-e16d5e2f79d7 --><h2>Scenario: Acute exacerbation of chronic obstructive pulmonary disease</h2><!-- end field 5631257a-041a-4295-874a-e16d5e2f79d7 -->","summary":"Covers the management of people experiencing an acute exacerbation of COPD.","htmlStringContent":"<!-- begin item 7796882d-9336-430b-ba4d-4a16905d243a --><!-- begin field da068436-d853-4406-9056-acd900adb50a --><p>From age 16 years onwards.</p><!-- end field da068436-d853-4406-9056-acd900adb50a --><!-- end item 7796882d-9336-430b-ba4d-4a16905d243a -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"84864d96-5f5a-5304-9f59-31bbd9d210e4","slug":"assessment","fullItemName":"Assessment","depth":3,"htmlHeader":"<!-- begin field 97ab17e7-0444-4c08-a611-7e13f646c25c --><h3>How should I assess a person with an acute exacerbation of COPD?</h3><!-- end field 97ab17e7-0444-4c08-a611-7e13f646c25c -->","summary":null,"htmlStringContent":"<!-- begin item fecdc2c7-f17e-44da-a84f-c59196cb0bfc --><!-- begin field 63413ca7-59d3-404f-b03e-225cdc3f297f --><ul><li><strong>If an acute exacerbation is suspected, assess its severity:</strong><ul><li><strong>Features suggestive of an <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-acute-exacerbation/\">acute exacerbation</a> include:</strong><ul><li>Worsening breathlessness.</li><li>Increased sputum volume and purulence.</li><li>Cough.</li><li>Wheeze.</li><li>Fever without an obvious source.</li><li>Upper respiratory tract infection in the past 5 days.</li><li>Increased respiratory rate or heart rate increase 20% above baseline.</li></ul></li><li><strong>A severe exacerbation may be suggested by:</strong><ul><li>Marked breathlessness and tachypnoea.</li><li>Pursed-lip breathing and/or use of accessory muscles at rest.</li><li>New-onset cyanosis or peripheral oedema.</li><li>Acute confusion or drowsiness.</li><li>Marked reduction in activities of daily living.</li></ul></li></ul></li><li><strong>Carry out a thorough clinical assessment:</strong><ul><li>Check vital signs (including temperature, oxygen saturations [using pulse oximetry], blood pressure and heart rate).</li><li>Assess for confusion or impaired consciousness.</li><li>Examine the chest.</li><li>Check ability to cope at home.</li></ul></li><li><strong>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/#when-to-admit\">hospital admission</a>.</strong></li><li><strong>Do not send sputum samples for culture routinely</strong>.</li><li><strong>Consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-acute-exacerbation/#differential-diagnosis\">other causes</a> of symptoms</strong> (such as myocardial infarction, worsening heart failure, pulmonary embolus and pneumonia).</li></ul><!-- end field 63413ca7-59d3-404f-b03e-225cdc3f297f --><!-- end item fecdc2c7-f17e-44da-a84f-c59196cb0bfc -->","subChapters":[{"id":"27f1e921-0a0b-54dc-8f82-f773c4613bad","slug":"basis-for-recommendation-d80","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6b64c5dc-9d38-40dd-8aca-7adfb33e2b23 --><h4>Basis for recommendation</h4><!-- end field 6b64c5dc-9d38-40dd-8aca-7adfb33e2b23 -->","summary":null,"htmlStringContent":"<!-- begin item d80afaab-8be4-4148-b678-551d5eda0418 --><!-- begin field dbf34b65-d2fb-4d98-a534-22209bb2ac8c --><p>The recommendations on assessment of a person with an acute exacerbation of COPD are largely based on the NICE clinical guidelines <em>Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018a</a>] and <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>], the clinical guidelines <em>COPD-X: concise guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>] and <em>Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BMJ Best Practice, 2018</a>].</p><ul><li>Prompt recognition, early diagnosis and treatment of exacerbations may prevent hospital admission, delay progression and improve quality of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>].</li><li>The recommendation that sputum should not be sent for culture routinely is based on NICE guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li></ul><!-- end field dbf34b65-d2fb-4d98-a534-22209bb2ac8c --><!-- end item d80afaab-8be4-4148-b678-551d5eda0418 -->","subChapters":[]}]},{"id":"9c18b354-961e-5174-ad65-8fe89f43a2a1","slug":"when-to-admit","fullItemName":"When to admit","depth":3,"htmlHeader":"<!-- begin field 9d675419-5960-48e5-bd86-37aaf36dea22 --><h3>When should I arrange hospital admission for a person with an acute exacerbation of COPD?</h3><!-- end field 9d675419-5960-48e5-bd86-37aaf36dea22 -->","summary":null,"htmlStringContent":"<!-- begin item 30df2258-35f4-4e76-8719-c187f3620439 --><!-- begin field 8990ac66-ae00-430e-91f5-6bf6f6654eb5 --><ul><li><strong>Consider emergency admission if the person has any of the following</strong><strong>:</strong><ul><li>Severe breathlessness.</li><li>Inability to cope at home (or living alone).</li><li>Poor or deteriorating general condition including significant comorbidity (such as cardiac disease or insulin-dependent diabetes).</li><li>Rapid onset of symptoms.</li><li>Acute confusion or impaired consciousness</li><li>Cyanosis.</li><li>Oxygen saturation less than 90% on pulse oximetry.<ul><li>Give oxygen (if available) while awaiting emergency transfer to hospital and monitor response with pulse oximetry — refer to local protocols (or follow instructions on the person's oxygen alert card if available).</li><li>Otherwise, initially give patients with COPD oxygen via a Venturi 24% mask at 2-3 l/min or Venturi 28% mask at a flow rate of 4 l/min or nasal cannula at a flow rate of 1-2 l/min (if a 24% mask is not available).</li><li>The target oxygen saturation should be 88– 92% in most cases.</li></ul></li><li>Worsening peripheral oedema.</li><li>New arrhythmia.</li><li>Failure of exacerbation to respond to initial treatment.</li><li>Already receiving long-term oxygen therapy.</li><li>Changes on chest X-ray.</li></ul></li><li><strong>Where available, hospital-at-home schemes may be appropriate as an alternative to admission.</strong></li></ul><!-- end field 8990ac66-ae00-430e-91f5-6bf6f6654eb5 --><!-- end item 30df2258-35f4-4e76-8719-c187f3620439 -->","subChapters":[{"id":"e443c763-17ed-5e09-b16e-c8ffbeaa21ff","slug":"basis-for-recommendation-cb7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6a8a78ed-0884-4d16-92c4-9d01e0971c90 --><h4>Basis for recommendation</h4><!-- end field 6a8a78ed-0884-4d16-92c4-9d01e0971c90 -->","summary":null,"htmlStringContent":"<!-- begin item cb760cf1-474f-4378-857d-7a685995578d --><!-- begin field a00b6172-f318-436b-bae5-68036c29318c --><p>The recommendations on when to admit a person with an acute exacerbation of chronic obstructive pulmonary disease (COPD) are largely based on the NICE clinical guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>], and the clinical guidelines <em>COPD-X: concise guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>], <em>Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Wedzicha, 2017a</a>] and <em>Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</p><ul><li>Recommendation on oxygen administration are taken from the British Thoracic Society guideline <em>BTS guideline for oxygen use in adults in healthcare and emergency settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BTS, 2017</a>] which states that:<ul><li>Provision of optimal oxygen therapy at the earliest possible opportunity during assessment and transfer to hospital of the acutely breathless patient is essential.</li><li>Clinicians should be aware that excessive oxygen therapy can be dangerous in some people with advanced COPD and administration of high oxygen concentrations in acute COPD can worsen hypercapnic respiratory failure and respiratory acidosis — target saturation (using pulse oximetry) is needed to ensure appropriate therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BTS, 2017</a>].</li><li>Oxygen alert cards and 24% or 28% Venturi masks should be issued to people with COPD who have had an episode of hypercapnic respiratory failure — content of the alert card should be specified by the physician in charge of the person’s care, based on previous blood gas results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BTS, 2017</a>].</li></ul></li></ul><!-- end field a00b6172-f318-436b-bae5-68036c29318c --><!-- end item cb760cf1-474f-4378-857d-7a685995578d -->","subChapters":[]}]},{"id":"40206124-e1cd-56ba-8554-93770299a7ba","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field 1eea2cad-0b57-4180-a642-e01082f21e35 --><h3>How should I treat a person with an acute exacerbation of COPD who does not require admission?</h3><!-- end field 1eea2cad-0b57-4180-a642-e01082f21e35 -->","summary":null,"htmlStringContent":"<!-- begin item 5159965e-5526-4e37-8673-9b135b21e2c5 --><!-- begin field ea919525-138b-441d-ab06-b22e3e76f106 --><ul><li><strong>If <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/#when-to-admit\">admission</a> is not indicated, advise the person to increase the doses or frequency of short-acting bronchodilators (not exceeding the maximum dose)</strong><strong>.</strong><ul><li>If possible, keep to the same delivery system (inhaler, inhaler with spacer or nebulizer) as is used on a day-to-day basis — take into account the dose of drug needed, the person's ability to use the device, and resources available to supervise therapy when considering choice of delivery system.</li><li>If the person is likely to become fatigued, a nebulizer may be appropriate (depending on availability and local protocols) — the driving gas for nebulised therapy should always be specified in the prescription.</li></ul></li><li><strong>If there are no contraindications, consider oral corticosteroids</strong> <strong>for people with a significant increase in breathlessness that interferes with daily activities.</strong><ul><li>Offer 30 mg oral prednisolone once daily for 5 days — discuss adverse effects of prolonged therapy.</li><li>Consider the need for osteoporosis prophylaxis for people requiring frequent courses of oral corticosteroids (3–4 courses per year).<ul><li>See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> and <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li></ul></li><li><strong>Consider the need for an antibiotic taking into account:</strong><ul><li>Severity of symptoms (particularly sputum colour changes and increase in volume or thickness beyond normal).</li><li>Risk of <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/background-information/complications/\">complications</a>.</li><li>Previous sputum culture and susceptibility results.</li><li>Risk of antimicrobial resistance and current antibiotic prophylaxis (treatment should be with an antibiotic from a different class).</li></ul></li><li><strong>First choice oral antibiotics include:</strong><ul><li>Amoxicillin 500 mg three times a day for 5 days.</li><li>Doxycycline 200 mg on first day, then 100mg once a day for 5-day course in total.</li><li>Clarithromycin 500 mg twice a day for 5 days.</li></ul></li><li><strong>If there is no improvement in symptoms on first choice taken for at least 2 to 3 days; guided by susceptibility and where <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/#when-to-admit\">admission</a> is not indicated:</strong><ul><li>Send a sputum sample for culture and susceptibility testing.</li><li>Offer an alternative first choice antibiotic from different class (guided by susceptibilities when available).</li></ul></li><li><strong>If the person is at higher risk of treatment failure </strong>(for example frequent antibiotic use; previous or current sputum culture with resistant bacteria or high risk of developing complications) consider prescribing co-amoxiclav 500/125 mg three times a day for 5 days — seek specialist advice if unsure.</li><li><strong>If an antibiotic is prescribed, give advice on:</strong><ul><li>Potential adverse effects, including diarrhoea.</li><li>When to seek medical help, for example if:<ul><li>Symptoms worsen rapidly or significantly <em>or</em></li><li>Symptoms do not start to improve within 2–3 days (or other agreed time) <em>or</em></li><li>They become systemically very unwell.</li></ul></li></ul></li><li><strong>If no antibiotic is given, advise the person to seek medical help immediately if:</strong><ul><li>Symptoms (such as sputum colour changes and increases in volume or thickness) worsen rapidly or significantly <em>or</em></li><li>Symptoms do not start to improve within an agreed time <em>or</em></li><li>They become systemically very unwell.</li></ul></li><li><strong>If a sputum sample has been sent and an antibiotic given:</strong><ul><li>Review the choice of antibiotic when results are available.</li><li>Only change the antibiotic according to susceptibility results if bacteria are resistant and symptoms are not improving.</li></ul></li><li><strong>Seek specialist advice if:</strong><ul><li>Symptoms are not improving with repeated courses of antibiotics <em>or</em></li><li>Bacteria resistant to oral antibiotics are identified <em>or</em></li><li>The person cannot take oral medication.</li></ul></li></ul><!-- end field ea919525-138b-441d-ab06-b22e3e76f106 --><!-- end item 5159965e-5526-4e37-8673-9b135b21e2c5 -->","subChapters":[{"id":"11bed873-9fd9-56af-81b2-b8136e7873a0","slug":"basis-for-recommendation-7b8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9be89842-26b3-4e74-9df1-b7f2f77cf9d6 --><h4>Basis for recommendation</h4><!-- end field 9be89842-26b3-4e74-9df1-b7f2f77cf9d6 -->","summary":null,"htmlStringContent":"<!-- begin item 7b8fcb99-c94f-4a58-9ce2-1dfb02b7a621 --><!-- begin field e011ad6d-2380-4f5e-b7f9-aeb1e67f78c5 --><p>The recommendations on treatments for exacerbations of chronic obstructive pulmonary disease (COPD) are largely based on the National Institute for Health and Clinical Excellence (NICE) clinical guidelines <em>Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018a</a>] and <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>], and the clinical guidelines <em>COPD-X: concise guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>] and <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</p><p><strong>Short-acting bronchodilators —</strong> clinical guidance from NICE, GOLD and the Lung Foundation Australia is in agreement on increasing the dose or frequency of use of inhaled medication for acute exacerbations of COPD.</p><ul><li>NICE did not review the evidence for bronchodilators specifically in the acute setting. However, NICE did review evidence on delivery systems for bronchodilators during exacerbations. A meta-analysis of randomized controlled trials (RCTs) found hand-held inhalers with a spacer and nebulizers to be equally effective at alleviating symptoms. NICE acknowledged that in very breathless people, a nebulizer may be more appropriate.</li></ul><p><strong>Oral corticosteroids </strong>— clinical guidance from NICE, GOLD and the Lung Foundation Australia are in agreement on the use of oral corticosteroids in moderate to severe exacerbations of COPD.</p><ul><li>NICE identified three systematic reviews and one subsequent RCT of oral corticosteroids for COPD exacerbations, although they noted limitations to the validity and generalizability of several of the included studies. A significant effect on forced expiratory volume in 1 second (FEV1) was demonstrated with oral corticosteroids compared with placebo with treatment duration of at least 3 days. Individual studies also found benefits in arterial partial pressure of oxygen (PaO2). Findings on the effect on duration of hospitalization were inconsistent, and no difference in mortality was demonstrated. People taking corticosteroids were more likely to have adverse effects (for example hyperglycaemia).</li><li>As risks are associated with long-term corticosteroid use; identified evidence showed no benefit from taking corticosteroids for more than 7 days and shorter courses of 5 days are routinely used in clinical practice already the NICE guideline development group recommend a duration of treatment of 5 days. The 2019 guideline review did not look at corticosteroid doses — the dose from the original 2004 recommendation was retained.</li></ul><p><strong>Antibiotics</strong> — guidance from NICE, GOLD and the Lung Foundation Australia recommend that where an infective exacerbation of COPD is suspected (based on change in clinical features such as increased volume and change in colour and consistency of sputum) antibiotic therapy should be considered.</p><ul><li>The NICE guideline committee on antimicrobial prescribing in acute exacerbations of COPD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018a</a>] agreed that:<ul><li>Many health professionals may not be aware of the limited benefit of antibiotics, and that many exacerbations are not caused by a bacterial infection.</li><li>It was not possible to identify which people with an acute exacerbation are more likely to benefit from antibiotics. However, based on expert consensus, the presence of sputum colour changes and increases in volume or thickness beyond the person's normal day-to-day variation appear to be important factors.</li><li>Antibiotics for an acute exacerbation of COPD should be considered on an individual patient basis with uncertain benefit of antibiotics balanced against severity of symptoms, need for hospital treatment, exacerbation and hospitalisation history, risk of complications, and previous sputum culture results.</li></ul></li><li>Recommendations on choice of first and second line antibiotics and duration of course are taken from the NICE guideline on <em>Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018a</a>]:<ul><li>Evidence for the choice of first-line or second-line antibiotics was based on a systematic review and meta-analysis of RCTs.</li><li>Where a person is receiving prophylactic antibiotics, antibiotic treatment for an acute exacerbation should be with an antibiotic from a different class.</li><li>Broader-spectrum antibiotics (some of which also have additional safety warnings) should be reserved for those at higher risk of treatment failure.</li></ul></li><li>The GOLD guideline states that when indicated, antibiotics can shorten recovery time, reduce risk of early relapse, treatment failure and hospital duration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</li></ul><!-- end field e011ad6d-2380-4f5e-b7f9-aeb1e67f78c5 --><!-- end item 7b8fcb99-c94f-4a58-9ce2-1dfb02b7a621 -->","subChapters":[]}]},{"id":"6c36ca78-7329-5fa3-86cc-8dcf94a23928","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 4a8e0f54-5d9f-496b-bd85-f1212d9338aa --><h3>How should I follow up a person who has had an exacerbation of COPD?</h3><!-- end field 4a8e0f54-5d9f-496b-bd85-f1212d9338aa -->","summary":null,"htmlStringContent":"<!-- begin item e62aae52-eea6-40b3-861a-2d9c093b4302 --><!-- begin field b0c060f0-92c4-40a1-af84-98c32fe7c930 --><ul><li><strong>Reassess people with an acute exacerbation of chronic obstructive pulmonary disease (COPD) if their symptoms worsen rapidly or significantly at any time. Consider:</strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-acute-exacerbation/#differential-diagnosis\">Other possible diagnoses</a>, such as pneumonia.</li><li>Symptoms or signs suggestive of a more serious illness or condition, such as cardiorespiratory failure or sepsis.</li><li>Previous antibiotic use which may have led to resistant bacteria.</li><li>The need for <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/#when-to-admit\">admission</a>.</li></ul></li><li><strong>Send a sputum sample for culture and sensitivity testing</strong> if symptoms have not improved following antibiotic treatment and this has not already been done.</li><li><strong>Follow up all people who have had an exacerbation of COPD</strong> when they are clinically stable (for example, 6 weeks after onset of exacerbation). At follow up:<ul><li>Assess any residual or changed symptoms — consider the need for further investigations (for example chest X-ray if the person has recurrent chest infections) to exclude other conditions.</li><li>Optimize <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/#non-pharmacological-treatments-inhaled-treatments\">non-pharmacological</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/#non-pharmacological-treatments-inhaled-treatments\">pharmacological management</a> to reduce the risk of further exacerbations.</li><li>Ensure the person knows how to use prescribed medications appropriately and assess for adverse effects.</li><li>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/#referral-to-a-respiratory-specialist\">referral to a respiratory specialist</a> and/or referral or re-<a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/#referral-for-pulmonary-rehabilitation\">referral for pulmonary rehabilitation</a>.</li><li>Offer a short course of <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/#treatment\">oral corticosteroids</a> and a short course of <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/acute-exacerbation/#treatment\">oral antibiotics</a> to keep at home as part of the person’s exacerbation action plan if they:<ul><li>Have had an exacerbation within the last year, and remain at risk of exacerbations.</li><li>Understand and are confident about when and how to take the medication, and are aware of associated risks and benefits.</li><li>Know to when to seek help and when to ask for replacements once medication has been used.</li></ul></li><li>For people who have used 3 or more courses of oral corticosteroids and/or oral antibiotics in the last year, investigate the possible reasons for this — consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">alternative causes</a>.</li><li>Review the person’s <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/stable-copd/#self-management-plan\">self-management plan</a>.</li></ul></li></ul><!-- end field b0c060f0-92c4-40a1-af84-98c32fe7c930 --><!-- end item e62aae52-eea6-40b3-861a-2d9c093b4302 -->","subChapters":[{"id":"22b9a155-ac81-552f-ada5-694db8c5752e","slug":"basis-for-recommendation-0bc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 33e211bf-5f5f-4dd6-ad28-5589b3e99c67 --><h4>Basis for recommendation</h4><!-- end field 33e211bf-5f5f-4dd6-ad28-5589b3e99c67 -->","summary":null,"htmlStringContent":"<!-- begin item 0bc954dc-6b16-4036-85a3-d88a611d8e44 --><!-- begin field 076a0482-4c53-40b5-84de-1f80b1e834ae --><p>The recommendations on follow-up of people after an acute exacerbation of chronic obstructive pulmonary disease (COPD) are largely based on the National Institute for Health and Clinical Excellence (NICE) clinical guidelines <em>Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018a</a>] and <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>], and the clinical guidelines <em>COPD-X: concise guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>] and <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</p><ul><li>The recommendations on choice of antibiotic are taken from the NICE guideline <em>Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018a</a>].</li><li>The recommendation to arrange a chest X-ray for people with recurrent chest infections is pragmatic, based on what CKS considers to be good medical practice.</li></ul><!-- end field 076a0482-4c53-40b5-84de-1f80b1e834ae --><!-- end item 0bc954dc-6b16-4036-85a3-d88a611d8e44 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}